Shah, N. N., Wang, M., Roeker, L. E., Patel, K., Woyach, J. A., Wierda, W. G., Ujjani, C. S., Eyre, T. A., Zinzani, P. L., Alencar, A. J., Ghia, P., Lamanna, N., Hoffmann, M. S., Patel, M. R., Flinn, I., Gerson, J. N., Ma, S., Coombs, C. C., Cheah, C. Y., Lech-Maranda, E., Fakhri, B., Kim, W. S., Barve, M. A., Cohen, J. B., Jurczak, W., Munir, T., Thompson, M. C., Tsai, D. E., Bao, K., Cangemi, N. A., Kherani, J. F., Walgren, R. A., Han, H., Ruppert, A. S. and Brown, J. R. (2020) “Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2024.285754.